The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
lung disease
[Image: chaunpis/istockphoto]
Fort Worth’s AyuVis Is One Step Closer to Protecting Pre-Term Babies from a Leading Cause of Death
by David Kirkpatrick | Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
by Lance Murray |
Mar 27, 2020
The investment from multiple sources, including local early-stage investor Hunt Technology Ventures, is the largest funding round by a startup this year in Dallas-Fort Worth.
MORE►
